Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 2/3 3Phase 1/2 2Phase 1 2Phase NA 1Phase 4 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Endocrine 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20venetoclax 18Vincristine 18apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × EC regimen × Clear all
NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.

Phase 2/3 Unknown
313 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03992911 2019-06-20

Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma

Peking University

Phase 2/3 Unknown
336 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01204437 2016-02-10

ICE-II

GBG Forschungs GmbH

Phase 2/3 Completed
400 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡